BRCA1 and metastatic prostate carcinoma: This includes BRCA1/2, as well as additional genes such as ATM, FANCA, CHEK2, PALB2, CDK12, and RAD51D. Due to this high prevalence of mutations, current National Comprehensive Cancer Network (NCCN) guidelines recommend germline testing for homologous recombination repair genes in patients with metastatic prostate cancer (38).